Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD. In this video ...

"Despite the fact that multiple new procedures have come to light, nothing has the same excellent outcomes as HoLEP," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses the key ...

All nine patients with stage III/IV ccRCC showed anti-tumor responses and remained disease-free three years post-vaccination. The vaccine induced durable T cell activation and immune responses against ...

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

Panelists discuss how FDA approvals have expanded options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), with pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene ...

“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R.

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Prior to recent therapeutic innovations in the bladder space, what challenges or unmet needs did you face when treating ...

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels. “The key here is I don’t believe that testosterone increases the risk of ...

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...